ArticleJournal of maxillofacial and oral surgery2025
Platelet Lymphocyte Ratio as a Prognosticator in Oral Cancer Patients.
Article in Journal of maxillofacial and oral surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To study the prognostic predictive value of the platelet lymphocyte ratio as a clinical parameter of the outcome of the Sudanese OSCC patients. Method: Forty two oral cancer patients were selected for the study. The patients surgically managed in the period December 2018 to June 2020. The PLR was recorded and correlated with :the status of surgical margins, the lymphovascular invasion, the extranodal extension, the microscopic depth and the patient's survival (dead/ alive). Result: A ratio of 170 was considered to be a cut off point of the PLR; as patients with a ratio higher than 170 were found to have a bad prognosis. Twenty-four patients (59.5%) had a PLR higher than 170. Patients with PLR equal to 170 or less have 45% decrease in the odds of survival and 57% decrease in the odds of having positive lymph nodes. Thirty-three percent passed away. Conclusion: The PLR is an affordable, practical and efficient way to predict an OSCC patient's overall survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.